Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) on Apr. 3 announced the pricing of its previously announced underwritten public offering of 11,325,000 shares of its common stock at an offering price of $2.21 per share. In connection with the offering, Catalyst has also granted the underwriters a 30-day option to purchase up to an additional 1,698,750 shares of common stock to cover over-allotments, if any. Net proceeds from the sale of the shares by Catalyst after underwriting discounts and commissions and other offering expenses are expected to be approximately $23.3 million. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), shares after opening at $2.29 moved to $2.51 on last trade day and at the end of the day closed at $2.40. Company price to cash ratio as 5.48. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), showed a positive weekly performance of 4.35%.
Research analysts at JMP Securities cut their target price on shares ofHorizon Pharma (NASDAQ:HZNP) from $22.00 to $21.00 in a report released on Friday, ARN reports. The firm currently has an “outperform” rating on the stock. JMP Securities’ target price indicates a potential upside of 38.89% from the company’s current price. Horizon Pharma Inc (NASDAQ:HZNP), shares fell 8.39% in last trading session and ended the day on $14.85. Horizon Pharma Inc (NASDAQ:HZNP), return on equity ratio is recorded as -85.30% and its return on assets is -41.40%. Horizon Pharma Inc (NASDAQ:HZNP), yearly performance is 513.64%.
Investors in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were disappointed when the Supreme Court decided to hear an appeal by Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA). The decision will mean that Momenta will have to delay the launch of their own generic version of Copaxone. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares moved down 3.81% in last trading session and was closed at $11.11, while trading in range of $ 10.83 – 12.13. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) year to date (YTD) performance is -37.16%.
Investors in Ironwood Pharmaceuticals Inc. (IRWD) saw new options become available this week, for the November 22nd expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IRWD options chain for the new November 22nd contracts and identified one put and one call contract of particular interest. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) weekly performance is 3.61%. On last trading day company shares ended up $4.02. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) distance from 50-day simple moving average (SMA50) is -21.13%. Analysts mean target Price for the company is $7.00.
Leave a Reply